1 Contrary to established metabolic pattern, a recent investigation of NNK metabolism produced in rat urine higher levels of 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone (NNK) and 4-(methylnitrosamino)-1-(3-pyri dyl)-1-butanol (NNAL) than their N-oxides, suggesting that reconversion of N-oxides could occur after urine formation.
2 To verify the possible role of bacteria in the reduction of NNK-N-oxide and NNAL-N-oxide to their respective parent compounds, NNK and NNAL, in smokers with urinary tract infection (UTI), the N-oxides were isolated from the urine of rats treated with [5-3H]NNK and individually incubated at 37°C with ten bacterial species in sterile human urine under different pH regimens. After incubation with the bacteria, aliquots of culture media were analyzed by high pressure liquid chromatography (HPLC) with radiochemical detection.
3 Escherichia coli, Enterobacter cloacae, Klebsiella pneumoniae and Proteus mirabilis possessed varying capacity to regenerate NNK and NNAL from their N- oxides while others showed no detectable reductive capability within 24 h.
4 This result constitutes the first experimental evidence that in tobacco users with concomitant UTI, bacterial regeneration of the procarcinogenic NNK and NNAL from their N-oxides could occur in the bladder leading to increased carcinogen burden in these individuals.
Hoffmann D., Brunnemann KD, Prokopczyk B., Djordjevic MVTobacco-specific N-nitrosamines and Areca-derived N-nitrosamines: chemistry, biochemistry, carcinogenicity, and relevance to humans. Journal of Toxicology and Environmental Health1994; 41: 1-52.
2.
Hecht SSMetabolic activation and detoxification of tobacco-specific nitrosamines - a model for cancer prevention strategies. Drug Metabolism Reviews1994; 26: 373-390.
3.
Morse MA et al. Characterization of a glucuronide metabolite of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and its dose-dependent excretion in the urine of mice and rats. Carcinogenesis1990; 11: 1819-1823.
4.
Hecht SS et al. Metabolism of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in the patas monkey: pharmacokinetics and characterization of glucuronide metabolites. Carcinogenesis1993; 14: 229-236.
5.
Richter E., Tricker ARNicotine inhibits the metabolic activation of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in rats. Carcinogenesis1994; 15: 1061-1064.
6.
Schulze J., Richter E., Binder U., Zwickenpflug W.Biliary excretion of 4-(methylnitrosamino)-l-(3'pyridyl)-1-butanone in the rat. Carcinogenesis1992; 13: 1961-1965.
7.
Carmella SG, Akerkar S., Hecht SSMetabolites of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in smokers' urine. Cancer Research1993; 53: 721-724.
8.
Kutzer C., Richter E., Oehlmann C., Atawodi SEEffect of nicotine and cotinine on NNK metbolism in rats. In: Effects of Nicotine on Biological Systems II: Advances in Pharmacological Sciences. Clarke PBS, Quik M, Thurau K & Adlkofer F (eds.), Birkhäuser Verlag, Basel, Boston, Berlin, pp 385-390, 1995.
9.
Hawksworth G. , Hill MJThe in vivo formation of N-nitrosamines in the rat bladder and their subsequent absorption. British Journal of Cancer1974; 29: 353-358.
10.
Radomski JL et al. Nitrosamine formation in bladder infections and its role in the etiology of bladder cancer. Journal of Urology1978; 120: 48-50.
11.
Ohshima H. et al. N-Nitrosamine formation in urinary tract infections. In: The Relevance of N-nitroso Compounds to Human Cancer: Exposures and Mechanisms. Bartsch H, O'Neill IK & Schulte-Hermann R (eds.), International Agency for Research on Cancer, Lyon, France, IARC Scientific Publications1987; 84: 384-390.
12.
Calmels S., Ohshima H., Bartsch H.Nitrosamine formation by denitrifying and non-denitrifying bacteria: implication of nitrite reductase and nitrate reductase in nitrosation catalysis. Journal of General Microbiology1988; 134: 221-226.
13.
Leach SA, Thompson M., Hill M.Bacterially catalysed N-nitrosation reactions and their relative importance in the human stomach. Carcinogenesis1987; 8: 1907-1912.
14.
Jenner P., Gorrod JW, Beckett AHThe absorption of nicotine-1'-N'-oxide and its reduction in the gastrointestinal tract in man. Xenobiotica1973; 3: 341- 349.
15.
Dajani RM, Gorrod JW, Beckett AHReduction in vivo of (—) -nicotine-1'-N-oxide by germ-free and conventional rats. Biochemical Pharmacology1975; 24: 648-650.
16.
Yi MJ, Sprouse CT, Bowman ER, McKennis H., jr. The relationship between the metabolism of (S)-cotinine-N-oxide and (S)-cotinine. Drug Metabolism and Disposition1977; 5: 355-362.
17.
Sepkovic DW et al. Short-term studies on the in vivo metabolism of N-oxides of nicotine in rats. Journal of Toxicology and Environmental Health1986; 18: 205-214.
18.
Djordjevic M., Fan J., Ferguson S., Hoffmann D.Self-regulation of smoking intensity. Smoke yields of the low-nicotine, low-'tar' cigarettes. Carcinogenesis1995; 16: 2015-2021.
